Summary
Boston Scientific Corporation (BSX) announced on May 15, 2014, the signing of a definitive agreement to acquire the Interventional Division of Bayer AG. This strategic move is expected to enhance Boston Scientific's portfolio and market position within the interventional cardiology and peripheral vascular segments. The transaction is subject to customary closing conditions and is anticipated to be completed in the second half of 2014. Investors should note that the press release detailing this acquisition is attached as Exhibit 99.1 to the filing. While the full financial terms are not disclosed in this 8-K, the acquisition signals Boston Scientific's commitment to growth and expansion through strategic inorganic opportunities, potentially leading to increased revenue streams and market share in key areas of its business.
Key Highlights
- 1Boston Scientific (BSX) has entered into a definitive agreement to acquire Bayer AG's Interventional Division.
- 2The acquisition is expected to strengthen BSX's position in interventional cardiology and peripheral vascular markets.
- 3The transaction is subject to standard closing conditions.
- 4The deal is projected to close in the second half of 2014.
- 5A press release regarding the acquisition is included as Exhibit 99.1 to the filing.